General information
    ACovPid:ACoVP100496
    Trivial Name:StRIP16
    Amino Acids Sequence:Ac-DNE-SPA-QWF-SPA-YHL-SPA-FFN-SPA-V-NH2
    Length:
    C-Terminal Modification:NH2: Amide;  
    N-Terminal Modification:Ac: Acetyl;  
    Chemical Modification:SPA: S-2-(4-pentenyl) alanine;  
    Peptide Source:

    Human Angiotensin Converting Enzyme 2 (hACE2) : 9606

    Source Description:
    Against Virus:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Inhibition Value Type:IC50
    Inhibitory Effect:>43.5
    Inhibitory Unit:µM
    Target Domain Name:RBD of SARS-CoV-2
    Assay:Pseudotyped virus infection inhibition assay (HT1080/ACE2 cells)
    Assay Description:The antiviral activity of the peptides was evaluated in single-cycle infection assay by infecting HT1080/ACE2 cells with the SARS-CoV-2 pseudovirus, as previously described with minor modifications (PMID: 32207377). Briefly, in 96-well culture plates, aliquots of SARS-CoV-2 at about 3,000 TCID50/well at a multiplicity of infection (MOI) of 0.1 were preincubated with escalating concentrations of the peptides for 30 min. Next, 2 × 104 cells were added to each well and incubated at 37°C. HT1080/ACE2 cells cultured with medium with or without the SARS-CoV-2 pseudovirus were included as positive and negative controls, respectively. The linear peptide NYBSP-C, StRIP16 (Tocris, Bristol, United Kingdom), which is a SARS-CoV-2-unrelated Rab8a GTPase-binding double-stapled peptide, and an anti-ACE2 MAb (AC384; catalog no. AG-20A-0037PF; AdipoGen Life Sciences, San Diego, CA) were used as controls. In the case of the anti-ACE2 MAb, the cells were preincubated with escalating concentrations of the MAb for 30 min and then infected with the pseudovirus SARS-CoV-2. Following 24 h of incubation, the cells were washed with 100 µl of PBS and lysed with 50 µl of lysis buffer (Promega). Twenty-five microliters of the lysates was transferred to a white plate and mixed with the same volume of Nano-Glo luciferase reagent (Promega). The luciferase activity was measured immediately with the Tecan Spark. The percent inhibition by the peptides and the IC50 (the half-maximal inhibitory concentration) values were calculated using GraphPad Prism 7.0 software (San Diego, CA). Additionally, to test the specificity of the double-stapled peptides, we evaluated their activity against pseudovirus VSV-G by following the infection protocol described above. Following 24 h of incubation, 25 µl of the lysates was transferred to a white plate and mixed with 50 µl of a luciferase assay reagent. The luciferase activity was immediately measured.
    Anti-CoV activity in vivo:
    Reference:33310780
    Comment:Pseudovirus preparation : To prepare pseudoviruses capable of single-cycle infection, 10 × 106 HEK293T/17 cells were transfected with a proviral backbone plasmid and an envelope expression vector by using FuGENE6 (Promega, Madison, WI) and following the manufacturer’s instructions. To obtain the SARS-CoV-2 pseudovirus, the cells were transfected with the HIV-1 Env-deleted proviral backbone plasmid pNL4-3ΔEnv-NanoLuc DNA and the pSARS-CoV-2-SΔ19 plasmid (30). For the VSV-G pseudovirus, the cells were transfected with the Env-deleted proviral backbone plasmid pNL4-3.Luc.R-E- DNA and the pHEF-VSV-G envelope expression vector. Pseudovirus-containing supernatants were collected 2 days after transfection and filtered, their titers were determined, and they were stored in aliquots at −80°C. Pseudovirus titers were determined to identify the 50% tissue culture infectious dose (TCID50) by infecting different cell types. For the titers in HT1080/ACE2 cells, 2 × 104 cells were added to 100-µl aliquots of serial 2-fold dilutions of pseudoviruses in a 96-well plate and incubated for 24 h. For the titers in A549/ACE2 cells, 1 × 104 cells were added to 100-µl aliquots of serial 2-fold dilutions of pseudoviruses in a 96-well plate and incubated for 48
    3D structure:

    Structure Experiment Verified:
    Similar Peptides:

    Target Domain information
    Target Domain Full Name:Receptor-binding domain (RBD) of Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) spike glycoprotein
    Target Type:glycoprotein
    UniprotID [Sequence]:

    P0DTC2 [319-541]

    Target Synonyms:Alternative name(s) for spike glycoprotein: E2 Peplomer protein S glycoprotein
    Target Source:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Target Structure:6LVN, 6LXT, 6LZG, 6M0J, 6M17, 6M1V, 6VSB, 6VW1, 6VXX, 6VYB, 6W41, 6WPS, 6WPT, 6X29, 6X2A, 6X2B, 6X2C, 6X6P, 6X79, 6XC2, 6XC3, 6XC4, 6XC7, 6XCM, 6XCN, 6XDG, 6XE1, 6XEY, 6XF5, 6XF6, 6XKL, 6XKP, 6XKQ, 6XLU, 6XM0, 6XM3, 6XM4, 6XM5, 6XR8, 6XRA, 6XS6, 6YLA, 6YM0, 6YOR, 6YZ5, 6YZ7, 6Z2M, 6Z43, 6Z97, 6ZB4, 6ZB5, 6ZBP, 6ZCZ, 6ZDG, 6ZDH, 6ZER, 6ZFO, 6ZGE, 6ZGG, 6ZGI, 6ZH9, 6ZHD, 6ZLR, 6ZOW, 6ZOX, 6ZOY, 6ZOZ, 6ZP0, 6ZP1, 6ZP2, 6ZP5, 6ZP7, 6ZWV, 6ZXN, 7A25, 7A29, 7A4N, 7A5R, 7A5S, 7A91, 7A92, 7A93, 7A94, 7A95, 7A96, 7A97, 7A98, 7AD1, 7BWJ, 7BYR, 7BZ5, 7C01, 7C2L, 7C8D, 7C8V, 7C8W, 7CAB, 7CAH, 7CAI, 7CAK, 7CAN, 7CDI, 7CDJ, 7CH4, 7CH5, 7CHB, 7CHC, 7CHE, 7CHF, 7CHH, 7CJF, 7CN9, 7CT5, 7CWM, 7CWN, 7CWO, 7CWS, 7CWU, 7DCC, 7DCX, 7DD2, 7DD8, 7DDD, 7DDN, 7DF3, 7DF4, 7DK3, 7DK4, 7DK5, 7DK6, 7DK7, 7DMU, 7JJC, 7JJI, 7JJJ, 7JMO, 7JMP, 7JMW, 7JV2, 7JV4, 7JV6, 7JVA, 7JVB, 7JVC, 7JW0, 7JWB, 7JWY, 7JX3, 7JZL, 7JZM, 7JZN, 7JZU, 7K43, 7K45, 7K4N, 7K8M, 7K8S, 7K8T, 7K8U, 7K8V, 7K8W, 7K8X, 7K8Y, 7K8Z, 7K90, 7K9Z, 7KDG, 7KDH, 7KDI, 7KDJ, 7KDK, 7KDL, 7KE4, 7KE6, 7KE7, 7KE8, 7KE9, 7KEA, 7KEB, 7KEC, 7KJ2, 7KJ3, 7KJ4, 7KJ5, 7KKK, 7KKL, 7KL9, 7KMB, 7KMS, 7KMZ, 7KNB, 7KNE, 7KNH, 7KNI, 7L02, 7L06, 7L09